Literature DB >> 21493945

A US policy perspective on oral preexposure prophylaxis for HIV.

Arleen A Leibowitz1, Karen Byrnes Parker, Mary Jane Rotheram-Borus.   

Abstract

Orally administered preexposure prophylaxis is an innovative and controversial HIV prevention strategy involving the regular use of antiretroviral medications by uninfected individuals. Antiretroviral medications protect against potential HIV infection by reducing susceptibility to the virus. Recent clinical trial results indicate that preexposure prophylaxis can be safe and efficacious for men who have sexual intercourse with men, yet there remain policy considerations surrounding costs, opportunity costs, and ethical issues that must be addressed before broad implementation in the United States.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21493945      PMCID： PMC3093264          DOI： 10.2105/AJPH.2010.300066

Source DB:  PubMed          Journal:  Am J Public Health        ISSN： 0090-0036            Impact factor:   9.308


  17 in total

1.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

2.  Non-occupational post exposure prophylaxis as a biobehavioral HIV-prevention intervention.

Authors:  S Shoptaw; E Rotheram-Fuller; R J Landovitz; J Wang; A Moe; D E Kanouse; C Reback
Journal:  AIDS Care       Date:  2008-03

Review 3.  Pre-exposure prophylaxis for HIV infection: what if it works?

Authors:  Lynn A Paxton; Tony Hope; Harold W Jaffe
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

4.  Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.

Authors:  A David Paltiel; Rochelle P Walensky; Bruce R Schackman; George R Seage; Lauren M Mercincavage; Milton C Weinstein; Kenneth A Freedberg
Journal:  Ann Intern Med       Date:  2006-12-05       Impact factor: 25.391

5.  Changes in sexual risk behavior among participants in a PrEP HIV prevention trial.

Authors:  Greg Guest; Dominick Shattuck; Laura Johnson; Betty Akumatey; Edith Essie Kekawo Clarke; Pai-Lien Chen; Kathleen M MacQueen
Journal:  Sex Transm Dis       Date:  2008-12       Impact factor: 2.830

6.  Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.

Authors:  Steven D Pinkerton; Jeffrey N Martin; Michelle E Roland; Mitchell H Katz; Thomas J Coates; James O Kahn
Journal:  Arch Intern Med       Date:  2004-01-12

Review 7.  Prevalence of unprotected anal intercourse among HIV-diagnosed MSM in the United States: a meta-analysis.

Authors:  Nicole Crepaz; Gary Marks; Adrian Liau; Mary M Mullins; Latrina W Aupont; Khiya J Marshall; Elizabeth D Jacobs; Richard J Wolitski
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

8.  Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.

Authors:  Kamal Desai; Stephanie L Sansom; Marta L Ackers; Scott R Stewart; H Irene Hall; Dale J Hu; Rachel Sanders; Carol R Scotton; Sada Soorapanth; Marie-Claude Boily; Geoffrey P Garnett; Peter D McElroy
Journal:  AIDS       Date:  2008-09-12       Impact factor: 4.177

Review 9.  A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy.

Authors:  John Hornberger; Mark Holodniy; Katherine Robertus; Michael Winnike; Erin Gibson; Eric Verhulst
Journal:  Med Decis Making       Date:  2007 Nov-Dec       Impact factor: 2.583

10.  HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.

Authors:  A David Paltiel; Kenneth A Freedberg; Callie A Scott; Bruce R Schackman; Elena Losina; Bingxia Wang; George R Seage; Caroline E Sloan; Paul E Sax; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2009-03-15       Impact factor: 9.079
View more
  20 in total

1.  Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention.

Authors:  Jaclyn M White; Matthew J Mimiaga; Douglas S Krakower; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2012-06-13       Impact factor: 5.078

2.  Effects of syndemics on HIV viral load and medication adherence in the multicentre AIDS cohort study.

Authors:  M Reuel Friedman; Ron Stall; Anthony J Silvestre; Chongyi Wei; Steve Shoptaw; Amy Herrick; Pamela J Surkan; Linda Teplin; Michael W Plankey
Journal:  AIDS       Date:  2015-06-01       Impact factor: 4.177

Review 3.  Are cultural values and beliefs included in U.S. based HIV interventions?

Authors:  Gail E Wyatt; John K Williams; Arpana Gupta; Dominique Malebranche
Journal:  Prev Med       Date:  2011-08-22       Impact factor: 4.018

Review 4.  Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges.

Authors:  James M McMahon; Julie E Myers; Ann E Kurth; Stephanie E Cohen; Sharon B Mannheimer; Janie Simmons; Enrique R Pouget; Nicole Trabold; Jessica E Haberer
Journal:  AIDS Patient Care STDS       Date:  2014-07-21       Impact factor: 5.078

5.  Is Insurance a Barrier to HIV Preexposure Prophylaxis? Clarifying the Issue.

Authors:  Emma Sophia Kay; Rogério M Pinto
Journal:  Am J Public Health       Date:  2019-11-14       Impact factor: 9.308

Review 6.  Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.

Authors:  E Jennifer Edelman; David A Fiellin
Journal:  Am J Prev Med       Date:  2013-01       Impact factor: 5.043

7.  Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.

Authors:  Jonathan D Fuchs; Magdalena E Sobieszczyk; Tamra Madenwald; Doug Grove; Shelly T Karuna; Michele Andrasik; Adam Sherwat; Gail Broder; Kenneth Mayer; Beryl Koblin; Scott Hammer
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07-01       Impact factor: 3.731

8.  Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: balancing methodological rigor and research ethics.

Authors:  Kristen Underhill
Journal:  Soc Sci Med       Date:  2013-03-27       Impact factor: 4.634

9.  Knowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at Canadian AIDS service organizations.

Authors:  Heather Senn; James Wilton; Malika Sharma; Shawn Fowler; Darrell H S Tan
Journal:  AIDS Res Hum Retroviruses       Date:  2013-06-22       Impact factor: 2.205

10.  Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV.

Authors:  Joel Milam; Sonia Jain; Michael P Dubé; Eric S Daar; Xiaoying Sun; Katya Corado; Eric Ellorin; Jill Blumenthal; Richard Haubrich; David J Moore; Sheldon R Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2019-01-01       Impact factor: 3.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.